Skip to main content
Clinical Trials/NCT04032262
NCT04032262CompletedNot Applicable

Characterization of Gastrointestinal and Neuroenteric Dysfunction in Parkinson's Disease

Augusta University2 sites in 1 country25 target enrollmentStarted: October 4, 2017Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
25
Locations
2
Primary Endpoint
Cortical Evoked Potential (CEP)

Study Overview

Brief Summary

This study focuses on the relationship between the brain and the gut, and additionally will foster collaboration between Movement Disorder experts and Neurogastroenterologists to provide critical information and lead to innovative therapies in the future to treat GI dysfunction of Parkinson's Disease.

Detailed Description

Parkinson's disease affects 1 million people in the US with a rising prevalence. In addition to neurological problems, patients with Parkinson's Disease often suffer from debilitating gastrointestinal (GI) symptoms related to delayed stomach emptying, gas/bloating, and constipation. GI complaints of patients suffering from Parkinson's Disease are poorly understood. This proposal aims to characterize GI disturbance in patients with Parkinson's Disease and provide deeper understanding by investigating symptoms, regional and whole gut transit, anorectal physiology, and the brain-gut axis. The investigator believes patients with Parkinson's Disease will show altered GI sensation, slower GI motility and demonstrate deranged regulation of the brain-gut axis correlated to severity of Parkinson's disease. Results from this study of GI motility and brain-gut axis will define a subset of Parkinson's Disease patients that can benefit from tailored treatment. This study will foster collaboration between Movement Disorder experts and Neurogastroenterologists to provide critical information and lead to innovative therapies in the future to treat GI dysfunction of Parkinson's Disease.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Diagnostic
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Presence of 2 of 3 cardinal features of PD (resting tremor, bradykinesia, and rigidity)
  • Hoehn and Yahr Scale stage I-IV
  • Men or women aged 18+
  • Stable dopaminergic treatment for ≥4 weeks.
  • Women of childbearing potential must agree to a urine pregnancy test at screening and to avoid pregnancy throughout the study.

Exclusion Criteria

  • Secondary parkinsonism.
  • Parkinson-plus syndromes.
  • Montreal Cognitive Assessment score <
  • Unstable dosage of drugs active in the cns (e.g., anxiolytics, antidepressants) during the 60 days before the visit.
  • Participation in drug studies within 30 days of screening.
  • Structural brain disease.
  • Women who are pregnant or likely to conceive (women with potential for pregnancy must use contraceptive measures to be included);
  • Active or personal history of epilepsy.
  • Acute illness or active, confounding medical, neurologic, or musculoskeletal conditions.
  • Alcoholism or other forms of drug addiction.
  • Significant prior gastrointestinal surgery.
  • Ongoing chemotherapy or other treatment for cancer.
  • Dysphagia
  • implanted or externally worn medical device such as, but not limited to, a pacemaker. (gastric stimulators, bladder stimulators, spinal stimulators, medication infusion devices, insulin pumps, continuous glucose monitors are permitted).

Outcomes

Primary Outcomes

Cortical Evoked Potential (CEP)

Time Frame: Single Visit, 3 hours

Bilateral amplitude (microvolts) for ano-rectal CEP responses

Motor Evoked Potential (MEP)

Time Frame: Single visit, 2 hours

Bilateral amplitude (microvolts) for ano-rectal MEP responses

Secondary Outcomes

  • Non-motor symptoms questionnaire(Single visit, 1 hour)
  • Stool diary(2 visits, 1 hour)
  • Anal sensorimotor function(Single visit, 2 hours)
  • Montreal Cognitive Assessment (MoCA)(Single visit, 1 hour)
  • Gastrointestinal motor function and transit(2 visits, 1hour)
  • Unified Parkinson Disease Rating Scale (UPDRS)(Single visit, 1 hour)
  • 36-Item Short Form Survey (SF-36)(Single visit, 1 hour)
  • Gastroparesis Cardinal Symptom Index (GCSI)(Single visit, 1 hour)
  • Eckdart score (ESS)(Single visit, 1 hour)
  • Rectal sensorimotor function(Single visit, 2 hours)
  • Breath testing(Single visit, 3 hours)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials